Vigonvita Life Sciences Co., Ltd. (蘇州旺山旺水生物醫藥股份有限公司, Stock Code: 2630) announced that the stabilization period for its Global Offering concluded on December 3, 2025. According to the company, there was no over-allocation of H Shares in the International Offering, and no stabilizing actions took place during the stabilization period.
The Sponsor-Overall Coordinator did not exercise the Over-allotment Option before it lapsed on December 3, 2025, resulting in no additional H Shares being issued. The company stated that it continues to meet the public float requirement under Rule 19A.13A of the Listing Rules.